Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
174 hedge funds and large institutions have $291M invested in Antares Pharma, Inc. in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 53 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
61% more capital invested
Capital invested by funds: $181M → $291M (+$110M)
6% more funds holding
Funds holding: 164 → 174 (+10)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 53
59% less call options, than puts
Call options by funds: $595K | Put options by funds: $1.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11.6M |
| 2 |
CWM
Centric Wealth Management
Chicago,
Illinois
|
+$11.3M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$1.94M |
| 4 |
Morgan Stanley
New York
|
+$1.27M |
| 5 |
BlackRock
New York
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.25M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$3.23M |
| 3 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
-$2.49M |
| 4 |
JP Morgan Chase
New York
|
-$2.11M |
| 5 |
AC
Armistice Capital
New York
|
-$1.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
176
Asymmetry Capital Management
San Francisco,
California
| – | -$3.23M | -1,194,530 | Closed |
|
|
MFAM
177
Motley Fool Asset Management
Alexandria,
Virginia
| – | -$2.49M | -877,667 | Closed |
|
|
AC
178
Armistice Capital
New York
| – | -$1.16M | -428,000 | Closed |
|
179
Renaissance Technologies
New York
| – | -$916K | -339,213 | Closed |
|
|
MWNA
180
Marshall Wace North America
New York
| – | -$396K | -147,025 | Closed |
|
|
HF
181
HRT Financial
New York
| – | -$320K | -118,784 | Closed |
|
|
EP
182
Eudaimonia Partners
Winchester,
Tennessee
| – | -$54K | -20,000 | Closed |
|
|
SS
183
Simplicity Solutions
Minneapolis,
Minnesota
| – | -$49K | -18,266 | Closed |
|
|
E
184
Ergoteles
New York
| – | -$47K | -17,400 | Closed |
|
|
AIM
185
Alambic Investment Management
Belvedere,
California
| – | -$45K | -16,769 | Closed |
|
|
AAS
186
Avantax Advisory Services
Dallas,
Texas
| – | -$42K | -15,500 | Closed |
|
|
CHAM
187
Clear Harbor Asset Management
Stamford,
Connecticut
| – | -$8.1K | -3,000 | Closed |
|
ATRS Hedge Fund Activity: Q4 2020 in Review
174 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2020, worth a combined $291M — up 61% from $181M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ATRS positions and 13 closed out — a net gain of 10 holders — while 50 added to existing stakes and 53 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $11.6M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $3.25M sold.
- 174 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2020, up from 164 in Q3 2020.
- Funds reported $291M of Antares Pharma, Inc. stock for Q4 2020, up 61% quarter-over-quarter.
- 23 funds opened new Antares Pharma, Inc. positions in Q4 2020 and 13 closed out, a net change of +10 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2020 was Rubric Capital Management (New York), an estimated $11.6M added.
- The largest Antares Pharma, Inc. seller in Q4 2020 was Stonepine Capital Management, an estimated $3.25M sold.
Based on aggregated 13F filings for Q4 2020.